Zydus Lifesciences : Record Date

May 20, 2022
Listing Department	Code: 532321
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001
Listing Department	Code: ZYDUSLIFE
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051
Re: Outcome of Board Meeting
Dear Sir,

The Board of Directors at their meeting held today i.e. May 20, 2022, based on the recommendations of Audit Committee, approved the audited financial results for the quarter / year ended on March 31, 2022.

In this regard, please find enclosed the following:

1. the audited financial results (standalone and consolidated) for the quarter / year ended on March 31, 2022, reviewed by the Audit Committee and taken on record by the Board of Directors pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations").
2. the Audit Reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company certifying the audit of the financial results (standalone and consolidated) of the Company for the quarter / year ended on March 31, 2022 pursuant to regulation 33 of the Listing Regulations.
3. press release proposed to be published in the newspapers in the matter of audited financial results for the quarter / year ended on March 31, 2022.

• Pursuant to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors-M/s. Deloitte Haskins & Sells LLP (Firm Registration No. 117366W/W-100018), Chartered Accountants have submitted their Audit Reports (both, standalone and consolidated) for the year ended on March 31, 2022 with an unmodified opinion.
• The Trading Window under SEBI Insider Trading Regulations, 2015 shall remain closed for trading till May 22, 2022 and shall reopen on and from May 23, 2022 for the Directors and Designated Persons.
• Twenty Seventh Annual General Meeting of the members of the Company is scheduled to be held at 10.00 a.m. on Wednesday, August 10, 2022 through Video Conference / Other Audio Visual Means.

• The Board of Directors at their meeting held today have recommended final dividend of Rs. 2.50/- (@ 250%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 10, 2022.
• In compliance with regulation 42(1) of the Listing Regulations, we inform that the Record Date has been fixed as Friday, July 29, 2022 to determine the list of shareholders entitled to receive the Final Dividend for the financial year 2021-22, recommended by the Board of Directors subject to the approval of the same by the members at the ensuing Annual General Meeting.
• The Company shall make the payment of dividend, subject to deduction of tax at source, on or after August 16, 2022 subject to the approval of the same by the shareholders at the ensuing Annual General Meeting scheduled to be held on August 10, 2022.
• The existing term of five years of Deloitte Haskins & Sells LLP, Chartered Accountants ("Deloitte") as the Statutory Auditors of the Company expires at the ensuing Annual General Meeting. Board of Directors, based on the recommendation of Audit Committee, approved the re-appointment of Deloitte as the Statutory Auditors for the second term of 5 (five) years from the conclusion of twenty seventh annual general meeting till the thirty second annual general meeting. Said re-appointment is subject to approval of the shareholders at the ensuing Annual General Meeting. Deloitte is registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018). Deloitte has around 4,000 professionals and staff. Deloitte has offices in Mumbai, Delhi, Kolkata, Chennai, Bangalore, Ahmedabad, Hyderabad, Coimbatore, Kochi, Pune, Jamshedpur and Goa. The registered office of Deloitte is One International Center, Tower 3, 27th to 32nd Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400013, Maharashtra, India.
• The financial results, audit reports and the press release will be available on the website of the Company www.zyduslife.com.
• The Board Meeting commenced at 12:10 p.m. and concluded at 1:10 p.m.

Please receive the information and disclosures in order.

Thanking you,

Yours faithfully,

For, ZYDUS LIFESCIENCES LIMITED

(Formerly known as Cadila Healthcare Limited)

DHAVAL NARENDR A SONI

Digitally signed by DHAVAL NARENDRA SONI Date: 2022.05.20 13:18:03 +05'30'

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above